(2R,3R,4R,5S,6R)-5-[(2S,3R,4R,5S)-5-[[(2R,3R,4R,5S)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxyoxolan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol

Term ID

CHEBI:151669

Synonyms

alpha-L-arabino-pentofuranosyl-(1->5)-alpha-L-arabino-pentofuranosyl-(1->4)-beta-D-gluco-hexopyranose
Araf(a1-5)Araf(a1-4)b-Glc
WURCS=2.0/2,3,2/[a2122h-1b_1-5][a211h-1a_1-4]/1-2-2/a4-b1_b5-c1

Definition

References

GlyTouCan:G52814PM

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (2R,3R,4R,5S,6R)-5-[(2S,3R,4R,5S)-5-[[(2R,3R,4R,5S)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxyoxolan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol

Phenotype where environments contain (2R,3R,4R,5S,6R)-5-[(2S,3R,4R,5S)-5-[[(2R,3R,4R,5S)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxyoxolan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol

Phenotype modified by environments containing (2R,3R,4R,5S,6R)-5-[(2S,3R,4R,5S)-5-[[(2R,3R,4R,5S)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxyoxolan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol

Phenotype affecting (2R,3R,4R,5S,6R)-5-[(2S,3R,4R,5S)-5-[[(2R,3R,4R,5S)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxyoxolan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol

Human Disease Model